GlassScriptPhysician profile
Manisha S Patel
NPI 1568538213
$1,562.23
in general payments reported to CMS, 2019-2025
20 companies · $368 in 2025
The $368 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46.92 · 2020: $55.41 · 2021: $46.08 · 2022: $403 · 2023: $317 · 2024: $326 · 2025: $368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $997 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.94 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $241.14 | 2022-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $184.30 | 2022-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $183.44 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $154.12 | 2024-2025 | |
| Amgen INC. | $124.36 | 2022-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $106.22 | 2021-2022 | |
| Vifor Pharma, INC. | $93.50 | 2022-2023 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.81 | 2023-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $63.15 | 2020-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $59.67 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $54.23 | 2019-2020 | |
| Glaxosmithkline, LLC. | $46.04 | 2020-2024 | Jesduvroq, Benlysta |
| Revance Therapeutics, INC. | $34.13 | 2024-2025 | Daxxify |
| Ardelyx, INC. | $30.94 | 2024-2025 | Ibsrela |
| Medtronic USA, INC. | $20.15 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $19.69 | 2021 | |
| Csl Behring | $19.00 | 2024 | Haegarda |
| Renalytix Ai, INC. | $17.62 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Akebia Therapeutics INC | $17.50 | 2025 | Vafseo |
| Scpharmaceuticals INC. | $14.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manisha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.